Interplay between hypoxia, RNA methylation, and HPV in head and neck squamous cell carcinomas: drivers of oncogenesis and resistance to therapy
EXCLI Journal · 10.12.2025 · 24 · 1767-1796
DOI: 10.17179/excli2025-8834 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 10.12.2025. Verfasst von Marcel Mohr und 7 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Molecular Medicine, Medical University of Lodz, Haller Square 1, 90-624 Lodz, Poland. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Head and neck squamous cell carcinoma (HNSCC) encompasses a diverse group of tumors with varying etiology, biology, and response to therapy. Among its subtypes, human papillomavirus positive HNSCC is associated with better prognosis and enhanced sensitivity to radiotherapy, chemotherapy, and immunotherapy. However, resistance still occurs and is often driven by complex molecular mechanisms that remain incompletely understood. Recent evidence highlights the pivotal role of RNA modifications—particularly N6-methyladenosine (m⁶A)—in regulating key processes such as gene expression, immune response, and treatment resistance. Dysregulation of m⁶A machinery, including methyltransferases (METTL3, METTL14), demethylases (FTO, ALKBH5), and m⁶A readers (YTHDFs, IGF2BPs), has been implicated in oncogenesis, immune evasion, and therapy failure in multiple cancers, including HNSCC. These epitranscriptomic changes intersect with hypoxia-driven signaling pathways, which reshape the tumor microenvironment, promote immunosuppression, and impair DNA repair, further contributing to resistance to conventional and targeted therapies. Moreover, in HPV-related HNSCC, viral oncoproteins modulate both RNA methylation and host immune dynamics, creating a unique biological context where m⁶A modifications may serve as mediators of HPV-specific oncogenic programs and therapeutic vulnerabilities. This review integrates current knowledge on the interplay between hypoxia, m⁶A RNA methylation, and HPV infection in HNSCC, emphasizing their combined role in shaping tumor progression and resistance. A deeper understanding of these pathways may offer new opportunities for biomarker discovery and the development of rational combination therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School of Molecular Medicine, Medical University of Lodz, Haller Square 1, 90-624 Lodz, Poland.
- Radiobiology Laboratory, Greater Poland Cancer Centre, Garbary 15 Street, 61-866 Poznan, Poland.
- Department of Head and Neck Surgery, Poznan University of Medical Sciences, Garbary 15 Street, 61-866 Poznan, Poland.
- Master Student at Adam Mickiewicz University, Uniwersytetu Poznańskiego 6 Street, 61-614 Poznan Poznan, Poland.
- Department of Molecular Biology and Genetics, Aarhus University, Nordre Ringgade 1, 8000 Aarhus Centrum, Denmark.
- Department of Dental Surgery, Periodontology and Oral Mucosa Diseases, Poznan University of Medical Sciences, Bukowska 70 Street, 60-812 Poznan, Poland.
Zitieren
APA
Mohr, M., Kozikowska, J., Petryszyn, Z., Ostrowska, K., Golusinska-Kardach, E., Golusinski, W., Suchorska, W., & Kulcenty, K. (2025). Interplay between hypoxia, RNA methylation, and HPV in head and neck squamous cell carcinomas: drivers of oncogenesis and resistance to therapy. EXCLI Journal, 24, 1767-1796. https://doi.org/10.17179/excli2025-8834
Vancouver
Mohr M, Kozikowska J, Petryszyn Z, Ostrowska K, Golusinska-Kardach E, Golusinski W, et al. Interplay between hypoxia, RNA methylation, and HPV in head and neck squamous cell carcinomas: drivers of oncogenesis and resistance to therapy. EXCLI Journal. 2025;24:1767-1796. doi:10.17179/excli2025-8834
BibTeX
@article{Mohr2025,
author = {Mohr, Marcel and Kozikowska, Julia and Petryszyn, Zuzanna and Ostrowska, Kamila and Golusinska-Kardach, Ewelina and Golusinski, Wojciech and Suchorska, Wiktoria and Kulcenty, Katarzyna},
title = {Interplay between hypoxia, RNA methylation, and HPV in head and neck squamous cell carcinomas: drivers of oncogenesis and resistance to therapy},
journal = {EXCLI Journal},
year = {2025},
volume = {24},
pages = {1767--1796},
doi = {10.17179/excli2025-8834}
}
EUVIMED